Clinical Trials Browser

Active not recruiting × HER2-positive Breast Cancer × Ado-Trastuzumab Emtansine × Clear all

NCT03975647 2025-12-10

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Phase 3 Active not recruiting

466 enrolled 17 charts

HER2-positive Breast Cancer